Core Insights - YD Bio Limited has successfully listed on the Nasdaq Global Market, enhancing its capital base and global profile while accelerating the commercialization of its diagnostic and regenerative medicine platforms [1][2] Company Overview - YD Bio Limited is a biotechnology company focused on advancing clinical trials, drug development, cancer prevention diagnostics, and therapies using stem cells and exosomes [3] - The company aims to improve patient outcomes through scientific innovation and precision medicine, and has expanded into the development and distribution of post-market auxiliary products [3] Strategic Partnerships - YD Bio has secured exclusive 20-year licenses from EG Biomed and 3D Global Biotech, which positions the company to scale its non-invasive cfDNA methylation tests for early cancer detection and exosome-based eye therapies globally [2] - The strategic alliances with EG BioMed Co., Ltd. and 3D Global Biotech Inc. provide a significant competitive advantage and support a promising pipeline targeting multi-billion-dollar markets [2]

Core Insights - BioVie Inc. presented findings on Bezisterim, indicating its potential to decrease biological age acceleration in Alzheimer's Disease by modulating DNA methylation of over 100 genes related to aging and diseases of aging [1][4]. Group 1: Bezisterim's Mechanism and Effects - Bezisterim modulates TNFα-driven inflammation, helping to reestablish homeostasis and affecting multiple genes simultaneously [4]. - The treatment resulted in significant age deceleration across various biological clocks after 30 weeks, including reductions of -3.16 years for SkinBloodClockAge and -4.12 years for PhenoAge [5]. - Bezisterim demonstrated modulation of inflammatory gene expression, reducing levels of inflammatory cytokines such as TNFα, IL-6, and IL-17 [5]. Group 2: Clinical Trials and Efficacy - BioVie is conducting ongoing studies to explore Bezisterim's potential in improving healthspan in normal aging and its effects on neurodegenerative diseases [4]. - In Alzheimer's Disease, Bezisterim-treated patients showed improved cognition and biomarker levels in a Phase 2 trial, with significant improvements in metabolic and inflammatory biomarkers compared to placebo [10][11]. - The company is also enrolling patients in a Phase 2 trial for Parkinson's Disease, with topline data expected in late 2025 or early 2026 [8]. Group 3: Safety and Tolerability - Bezisterim is not immunosuppressive and has shown favorable safety and tolerability profiles in clinical trials for Alzheimer's Disease and Parkinson's Disease [6][7].